The role of the contact system in the pathogenesis of septic shock

Sepsis

Volumn 3, Issue 2, 1999, Pages 111-118

  Hack, C Erik ^a,c   Colman, Robert W ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; DESMOPRESSIN; HIGH MOLECULAR WEIGHT KININOGEN; PREKALLIKREIN;

ARTICLE; BLOOD CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HYPOTENSION; INFLAMMATION; REGULATORY MECHANISM; SEPTIC SHOCK;

EID: 0033503085     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009895315442     Document Type: Article

References (106)

1. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. J Biol Chem 1991;266: 7353-7358.
2. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991;253:909-912.
3. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Sem Hematol 1992;29:159-169.
4. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991; 30:10363-10370.
5. Minnema MC, Pajkrt D, Wuillemin WA, Roem D, Bleeker WK, Levi M, Van Deventer SJH, Hack CE, ten Cate H. Activation of factor XI without detectable contact activation in experimental human endotoxemia. Blood 1998;92:3294-3301
6. Borne PAKr von dem, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995;86:3035-3042.
7. Kaplan AP. The intrinsic coagulation, fibrinolytic and kinin-forming pathways of man. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders, 1985:95-114.
8. Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984;73: 1249-1253.
9. Kozin F, Cochrane CG. The contact activation system of plasma: Biochemistry and pathophysiology. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press Ltd, 1988:101-120.
10. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998;101:10-14.
11. Muller-Esterl W, Fritz H, Machleidt W, Ritonja A, Brzin J, Kotnik M, Turk V, Kellerman J, Lottspeich F. Human plasma kininogens are identical with alpha-cysteine proteinase inhibitors. FEBS Lett 1985;182:310-314.
12. Muller-Esterl W. Novel functions of the kininogens. Semin Thromb Hemost 1987;13:115-126.
13. Mandle R Jr, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976;73: 4179-4183.
14. Thompson RE, Mandle R, Kaplan AP. Studies of binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci USA 1979;76:4862-4866.
15. Thompson RE, Mandle R Jr, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977;60:1376-1380.
16. Kerberiou DM, Bouma BN, Griffin JH. Immunochemical studies of human high molecular weight kininogen and of its complexes with prekallikrein or kallikrein. J Biol Chem 1980;255:3952-3958.
17. Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII). Proc Natl Acad Sci USA 1978;75:1998-2002.
18. Tans G, Rosing J. Structural and functional characterisation of factor XII. Semin Thromb Hemost 1987;13:1-14.
19. Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982;257:1779-1784.
20. Wiggins RC, Bouma BN, Cochrane CG, Griffin JH. Role of high molecular weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc Natl Acad Sci USA 1977;74:4636-4640.
21. Van Iwaarden F, Bouma BN. Role of high molecular weight kininogen in contact activation. Semin Thromb Hemost 1987;13:15-24.
22. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987;70:1-15.
23. Scott CF, Silver LD, Schapira M, Colman RW. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest 1984;73:954-962.
24. Citarella F, Wuillemin WA, Lubbers YTP, Hack CE. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 1997;99:197-205.
25. Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation. Blood 1998;91:516-528.
26. Rojkaer R, Hasan AAK, Motta G, Schousboe I, Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998;80:74-81.
27. Colman RW, Schmaier AH. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1998;90:3819-3843.
28. Hack CE. The role of factor XII in contact system activation. Blood 1998;92:703-704.
29. Nuijens JH, Huijbregts CCM, Cohen M, Navis GO, de Vries A, Eerenberg AJM, Bakker JC, Hack CE. Detection of activation of the contact system of coagulation in vitro and in vivo: Quantitation of activated Hageman factor-C1-inhibitor and kallikrein-C1-inhibitor complexes by specific radioimmunoassays. Thromb Haemost 1987;58:778-785.
30. Nuijens JH, Huijbregts CCM, Eerenberg AJM, Abbink JJ, Strack van Schijndel RJM, Felt-Bersma RJF, Thijs LG, Hack CE. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 1988;72:1841-1848.
31. Kaufman N, Page JD, Pixley RA, Schein R, Schamaier AH, Colman RW. α2-Macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991;77:2660-2667.
32. Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen R, Arnout J, eds. Thrombosis and Haemostasis XIth Congress. Leuven: Leuven University Press, 1987:227-265.
33. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Thromb Haemost 1987;13:50-68.
34. Jurg M, Binder BR. Kinetic analysis of plasminogen activation by purified plasma kallikrein. Thromb Res 1985;39: 323-331.
35. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1969;35:273-278.
36. Goldsmith GH, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 1978;62:54-60.
37. Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986;261:3486-3489.
38. Binnema DJ, Dooijewaard G, Turion PNC. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. Thromb Haemost 1991;65:144-148.
39. Hauert J, Nicoloso G, Schleuning WD, Bachman F, Schapira M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: A molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood 1989;73:994-999.
40. Loza JP, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: A mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 1994;71:347-352.
41. Lin Y, Harris RB, Yan W, McCrae KR, Zhang H, Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cells surfaces and subsequent urokinase-dependent plasmin formation. Blood 1997;90:690-697.
42. Ratnoff OD, Busse RJ Jr, Sheon RP. The demise of John Hageman. N Engl J Med 1968;279:760-761.
43. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine 1983;62: 248-255.
44. Lammle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency. A study on 74 subjects from 14 Swiss families. Thromb Haemost 1991;65:117-121.
45. Levi M, De Boer JP, Roem D, Ten Cate JW, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP: Quantitative assessment of plasmin-α2-antiplasmin complexes with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992;67:111-116.
46. Levi M, Hack CE, De Boer JP, Brandjes DPM, Buller HR, ten Cate WJ. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 1991;88:1155-1160.
47. Yamamoto T, Cochrane CG. Guinae pig Hageman factor as a vascular permeability enhancement factor. Am J Pathol 1981;105:164-175.
48. Wachtfogel YT, Kucich U, James HV, Scott CF, Shapira M, Zimmerman M, Cohen AB, Colman RW. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983;72:1672-1677.
49. Ichinose M, Barnes PJ. Bradykinin-induced airway microvascular leakage and bronchoconstriction are mediated via a bradykinin B2 receptor. Am Rev Respir Dis 1990;142:1104-1107.
50. Mason DT, Melmon KL. Effects of bradykinin on fore-arm venous tone and vascular resistance in man. Circ Res 1965; 17:106-113.
51. Berg T, Schlichting E, Ishida H, Carretero OA. Kinin antagonist does not protect against the hypotensive response to endotoxin, anaphylaxis or acute pancreatitis. J Pharmacol Exp Ther 1989;251:731-734.
52. Ahluwalia A, Perretti M. Involvement of bradykinin B1 receptors in the polymorphonuclear leukocyte accumulation induced by IL-1α in vivo in the mouse. J Immunol 1996; 156:269-274.
53. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
54. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997;77:522-525.
55. Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical vein. Thromb Res 1980;18:787-795.
56. Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, Scott CF, De Agostini A, Burger D, Schapira M. Effect of cleavage of the heavy chain of human plasma kallikrein and its functional properties. Blood 1985;65: 311-318.
57. Kaplan AP, Kay AB, Austen KF. A prealbumin activator pf prekallikrein. II. Appearance of chemotactic activity for neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med 1972;135:81-97.
58. Schapira M, Despland E, Scott CF, Boxer LA, Colman RW. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982;69:1199-1202.
59. Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986;67:1731-1737.
60. Ghebrehiwet B, Randazzo BP, Dunn JT. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983;71:1450-1455.
61. Ghebrehiwet B, Silverberg M, Kaplan AP. Activations of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981;153:665-676.
62. Kalter ES, van Dijk WC, Timmermans A, Verhoef J, Bouma BN. Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 1983;148:692-697.
63. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974;140:797-811.
64. Herwald H, Morgelin M, Olsen A, Rhen M, Dahlback B, Muller-Esterl W, Bjorck L. Activation of the contact system on bacterial surfaces. A clue to serious complications in infectious diseases. Nat Med 1998;4:298-302.
65. Kimball HR, Melmon KL, Wolff SM. Endotoxin-induced kinin production in man. Proc Soc Exp Biol Med 1972; 139:1078-1087.
66. Muller-Berghaus G, Schneberger R. Hageman factor activation in the generalized Schwartzman reaction induced by endotoxin. Br J Haematol 1971;21:513-522.
67. McKay DG, Muller-Berghaus G, Cruse V. Activation of Hageman factor by ellagic acid and the generalized Schwartzman reaction. Am J Pathol 1969;54:393-402.
68. Nies AS, Forsyth RP, Williams HE, Melmon KL. Contribution of kinins to endotoxin shock in unanesthitized Rhesus monkeys. Circ Res 1968;22:155-164.
69. Mason JM, Kleeberg V, Dolan P, Colman RW. Plasma kallikrein and Hageman factor in gram-negative bacteremia. Ann Intern Med 1970;73:545-551.
70. Pixley RA, De La Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor FB Jr. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992;140:897-906.
71. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB Jr, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61-68.
72. Jansen PM, Pixley RA, Brouwer M, De Jong IW, Chang ACK, Hack CE, Taylor FB Jr, Colman RW. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87:2337-2344.
73. Colman RW, Flores DN, DeLa Cadena RA, Scott CA, Cousens L, Barr PJ, Hoffman IB, Kueppers F, Idell S, Pisarello J. Recombinant alpha-1-antitrypsin Pittsburgh attenuates experimental gram-negative septicemia. Am J Pathol 1988;130:418-428.
74. Guerrero R, Velasco F, Rodriquez M, Lopez A, Rojas R, Alvarez MA, Villalba R, Rubio V, Torres A, Del Castillo D. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest 1993;91:2754-2760.
75. De La Cadena RA, Suffredini AF, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW. Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993;81:3313-3341.
76. Van Deventer SJH, Buller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2526.
77. Van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, Van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, Ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-1626.
78. Colman RW, Edelman R, Scott CF, Gilman RM. Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 1978;61:287-296.
79. Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 1982; 9:491-497.
80. Kalter ES, Daha MR, Ten Cate JW, Verhoef J, Bouma BN. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:1019-1027.
81. Robinson JA, Kloduycky ML, Lock HH, Racic MR, Gunner RM. Endotoxin, prekallikrein, complement and systemic vascular resistance sequential measurements in man. Am J Med 1975;59:61-67.
82. Hesselvik JF, Blomback M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: Relation to outcome. Crit Care Med 1989;17:724-733.
83. Laemmle B, Tran TH, Ritz R. Plasma prekallikrein, factor XII, antithrombin III, C1-inhibitor and α2-macroglobulin in critically ill patients with suspected disseminated intravascular cragulation (DIG). Am J Clin Pathol 1984;82:396-404.
84. Martinez-Brotons F, Oncins JR, Mestres J, Amargos V, Reynaldo C. Plasma kallikrein-kinin system in patients with uncomplicated and septic shock. Comparison with cardiogenic shock. Thromb Haemost 1987;58:709-713.
85. Wilson RF, Farag A, Mammen EF, Fujii Y. Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients. Surgery 1989;55:450-456.
86. Wilson RF, Mammen EF, Robson MC, Heggers JP, Soullier G, DePoli PA. Antithrombin, prekallikrein, and fibronectin levels in surgical patients. Arch Surg 1985;121:635-640.
87. Hack CE, Nuijens JH, Strack van Schijndel RJM, Abbink JJ, Eerenberg AJM, Thijs LG. A model for the interplay of inflammatory mediators in sepsis: A study in 48 patients. Intensive Care Med 1990;16:187-191.
88. Pixley RA, Zellis S, Bankes P, DeLa Cadena RA, Page JD, Scott CF, Kappelmayer J, Wyshock EG, Kelly JJ, Colman RW. Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. Crit Care Med 1995;23:41-51.
89. Abbink JJ, Nuijens JH, Eerenberg AJM, Huijbregts CCM, Strack van Schijndel RJM, Thijs LG, Hack CE. Quantification of functional and inactivated α2-macroglobulin in sepsis. Thromb Haemost 1991;65:32-39.
90. Wuillemin WA, Fijnvandraat K, Derkx BHF, Peters M, Vreede W, ten Cate H, Hack CE. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995;74:1436-1441.
91. Hack CE, Voerman HJ, Eisele B, Keinecke H-O, Nuijens JH, Eerenberg AJM, Ogilvie A, Strack van Schijndel RJM, Delvos U, Thijs LG. C1-esterase inhibitor substitution in sepsis. Lancet 1992;339:378.
92. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985;260:1723-1729.
93. De Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-Inhibitor. J Clin Invest 1984;73:1542-1549.
94. van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983;71:149-158.
95. Wuillemin WA, Minnema MC, Meijers JCM, Roem D, Eerenberg AJM, Nuijens JH, ten Cate H, Hack CE. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995;85:1517-1526.
96. Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM, Schreuder WO, Felt-Bersma RJF, Abbink JJ, Thijs LG, Hack CE. Proteolytic inactivation of plasma C1-Inhibitor in sepsis. J Clin Invest 1989;84:443-450.
97. Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaier AH, Colman RW. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 1988;112:270-277.
98. Brower MS, Harpel PC. Proteolytic cleavage and inactivation of α2-plasmin inhibitor and C1-inactivator by human polymorphonuclear leucocyte elastase. J Biol Chem 1982;257:9849-9854.
99. De Boer JP, Creasey AA, Chang A, Roem D, Eerenberg AJM, Hack CE, Taylor FB Jr. Activation of the complement system in baboons challenged with live E. coli: Correlation with mortality and evidence for a biphasic activation pattern. Infect Immun 1993;61:4293-4301.
100. Egbring R, Schmidt W, Fuchs G, Havermann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977;49:219-231.
101. Duswald KH, Jochum M, Schramm W, Fritz H. Released granulocytic elastase: Indicator of pathobiochemical alterations in septicemia after abdominal surgery. Surgery 1985;98:892-898.
102. Seitz R, Wolf M, Egbring R, Radtke K-P, Liesenfeld A, Pittner P, Havemann K. Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections. Eur J Haematol 1987;38:231-240.
103. Jochum M, Witte J, Duswald KH, Inthorn D, Welter H, Fritz H. Pathobiochemistry of sepsis: Role of proteinases, proteinase inhibitors and oxidizing agents. Behring Inst Mitt 1986;79:121-130.
104. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982;69:462-468.
105. Harpel PC, Lewin MF, Kaplan AP. Distribution of plasma kallikrein between C1-inhibitor and α2-macroglobulin in plasma utilizing a new assay for α2-macroglobulin-kallikrein complexes. J Biol Chem 1985;260:4257-4263.
106. De Boer JP, Creasey AA, Chang A, Abbink JJ, Roem D, Eerenberg AJM, Hack CE, Taylor FB Jr. Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neuthropilic proteinases in sepsis: Studies using a baboon model. Infect Immun 1993;61:5035-5043.